deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03830866

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA)

A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer

Sponsor: AstraZeneca

Conditions Locally Advanced Cervical Cancer
Interventions Carboplatin Cisplatin Durvalumab external beam radiation therapy (EBRT) + brachytherapy
Updated 36 times since 2019 Last updated: Jun 28, 2024 Started: Feb 15, 2019 Primary completion: Jan 20, 2022 Completion: Jul 3, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Locally Advanced Cervical Cancer, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 36 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Sep 2023 · 4 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 5 months · monthly snapshot

Change History

36 versions recorded

  1. Mar 2026 — Present [monthly]

    Completed PHASE3

  2. Feb 2026 — Mar 2026 [monthly]

    Completed PHASE3

  3. Dec 2025 — Feb 2026 [monthly]

    Completed PHASE3

  4. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  5. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

▶ Show 31 earlier versions

  1. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE3

  2. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE3

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. May 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Nov 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  8. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Mar 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  10. Dec 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  11. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  12. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  13. Feb 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  14. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  15. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  16. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  17. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  18. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  19. Jun 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  20. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  21. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  22. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

  23. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  24. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  25. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  26. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  27. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  28. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  29. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  30. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  31. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

    First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Alc. Cuauhtémoc, Mexico , Ann Arbor, United States , Antofagasta, Chile , Arkhangelsk, Russia , Augusta, United States , Baguio City, Philippines , Barretos, Brazil , Bialystok, Poland , Budapest, Hungary and 80 more locations